Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

22.64 -1.70 (-6.96%)
Delayed Quote Updated: 3:52 PM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcus Biosciences, Inc. Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
News headline image
Earnings Scheduled For February 28, 2023 ↗
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
Where Arcus Biosciences Stands With Analysts ↗
 
Via Benzinga
Expert Ratings for Arcus Biosciences ↗
 
Via Benzinga
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Participate at Upcoming Virtual Investor Events
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Can The No. 1 Pharma Stock, Merck, Continue Its Blazing Run In 2023? ↗
Merck has a number of efforts in the works to help avoid a Keytruda generics pitfall. 
Via Investor's Business Daily
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Stock Market Falls Sharply Again As Tesla Dives, Micron Hits Chips; Nike, FedEx Strong: Weekly Review ↗
The market uptrend is under pressure. 
Via Investor's Business Daily
News headline image
Gilead Sciences (GILD) Stock Falls on Lung Cancer Drug Data ↗
Although Gilead Sciences produced meaningful results regarding a lung cancer drug test, the competitive shortfall hurt GILD stock. 
Via InvestorPlace
News headline image
Dow Jumps 150 Points; Crude Oil Rises 1% ↗
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 150 points on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Nasdaq Edges Lower; Gold Rises 1.5% ↗
U.S. stocks traded mixed midway through trading, with the S&P 500 and the Nasdaq Composite moving lower on Tuesday. 
Via Benzinga
News headline image
Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who... 
Via Benzinga
News headline image
Arcus Biosciences, FuelCell Energy And Some Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche ↗
Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. 
Via Investor's Business Daily
News headline image
US Stocks Edge Higher; Dow Rises 50 Points ↗
U.S. stocks traded mostly higher this morning, with the Dow Jones gaining around 50 points on Tuesday. 
Via Benzinga
News headline image
Gilead-Arcus Partnered Domvanalimab Combo Study Show Improved Progression-Free Survival In Lung Cancer Patients ↗
 
Via Benzinga
News headline image
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:RCUS),(NASDAQ:AZN),(NYSE:BMY),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges ↗
Gilead and Arcus notched another win for their cancer program on Monday. GILD stock briefly hit a four-year high as RCUS stock gapped higher. 
Via Investor's Business Daily
News headline image
Gilead-Arcus Biosciences Partnered Lung Cancer Therapy Shows Continuous Positive Efficacy Measures ↗
 
Via Benzinga
News headline image
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch ↗
Sales accelerated, again, in the third quarter. Here's what the company and analysts are watching. 
Via Investor's Business Daily
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022 ↗
Upgrades 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.